NCATS scientists used RNA interference technology to reveal genes that may represent new targets for treating mitochondrial disorders, including Parkinson’s.
Yale researchers used CTSA support and imaging technology to evaluate how the brain responds to sugar — an approach that could lead to the development of new biomarkers for obesity.
BrIDGs enables researchers to access critical resources needed for the development of new therapeutic agents. Apply between Nov. 1, 2013, and Jan. 10, 2014.
The awards, which expand the CTSA consortium's reach to New Hampshire, will help translate basic scientific discoveries into new treatments to improve health.
How is NCATS advancing translational research? Learn more about the Center's work and some of its early successes.
MORE CENTER NEWS
New e-book sheds light on rare disease and NCATS-led clinical trial to test new treatment.
Pamela M. McInnes, D.D.S., will become the NCATS deputy director on Jan. 12, 2014.
- NIH Reminds Applicants to Use Updated Electronic Application Forms (FORMS-C) for F, K, T and D Submissions with Due Dates on/after January 25, 2014
- NIH Will Require Use of Research Performance Progress Report (RPPR) for All Multi-Year Funded Awards
- Application Due Date Adjustments Based On Grants.gov Scheduled Downtime December 6-9, 2013
- More Funding & Notices...
- Trials: A Desperate Fight to Save Kids & Change Science • Wall Street Journal
- AesRx Presents Phase 1/2a Trial Data of Anti-Sickling Agent Aes-103 at ASH • AesRx
- In U.S. First, Stanford Researchers Record Data from Brain of Ambulatory Parkinson's Patient • Stanford School of Medicine
- More News & Events...
IN THE SPOTLIGHT
Toxicology in the 21st Century
The Tox21 program, a collaborative initiative among NIH, the Food and Drug Administration, and the Environmental Protection Agency, is designed to test 10,000 chemicals and evaluate their potential to cause health problems.